Sign in
Taking people in United StatesPhase 1/2

Added drugs for obstructive sleep apnea that remains despite device use

Tests added drugs for obstructive sleep apnea remaining despite device use.

Key facts

Who runs it
Brigham and Women's Hospital
Where
Boston, United StatesSee the site
Trial code
Registry title
Rescue Pharmacotherapy for OSA
Status
Recruiting
Phase
Phase 1/2
People taking part
70 people, planned
Started
1 Jul 2023
Planned end
30 Oct 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Placebo
  • Acetazolamide
  • Trazodone
  • Atomoxetine and eszopiclone
Record updated
15 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose obstructive sleep apnea is still present despite a mouth device (MAD) or nerve stimulation (HGNS). They will test an added drug or placebo.

Age
21 Years to 70 Years
Sex
All
Disease stage
Obstructive sleep apnea that persists on MAD or HGNS therapy, with a residual AHI ≥ 15 events/hr (breathing pauses per hour).
Earlier treatment
Must have had MAD (mandibular advancement device) or HGNS (hypoglossal nerve stimulation) therapy that did not work well enough.
Biomarker or test result
Residual AHI ≥ 15 events/hr on MAD or HGNS therapy.

Main reasons for not taking part

  • Other breathing or sleep disorders, such as central sleep apnea, low oxygen when awake (SaO2 < 92%), narcolepsy or periodic limb movements
  • Any unstable major medical condition
  • Taking drugs that affect breathing (such as opioids or benzodiazepines), or SSRIs/SNRIs
  • Serious heart, kidney or liver disease, severe high blood pressure, or other reasons the study drugs cannot be used
  • Pregnancy or breast-feeding

The registry criteria, word for word

Show all 51 criteriaShow less

Who can take part

  • Individuals who have failed MAD or HGNS therapy, defined as a residual AHI ≥ 15 events/hr on MAD or HGNS therapy

Who cannot take part

  • Medications expected to stimulate or depress respiration (including opioids, barbiturates, benzodiazepines, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid)
  • use of monoamine oxidase inhibitors
  • use of monoamine oxidase inhibitors
  • Sleep disordered breathing or respiratory disorders other than obstructive sleep apnea:; central sleep apnea (>50% of respiratory events scored as central), chronic hypoventilation/hypoxemia (awake SaO2 < 92% by oximetry) due to chronic obstructive pulmonary disease or other respiratory conditions
  • Other sleep disorders: periodic limb movements (periodic limb movement index > 20/hr), narcolepsy, or parasomnias
  • Any unstable major medical condition
  • bipolar disorder, mania, psychosis
  • pre-existing seizure disorders
  • clinically-significant kidney disorders
  • clinically-significant liver disorders
  • clinically-significant cardiovascular conditions
  • severe hypertension (SBP>180 mmHg or DBP>110 mmHg measured at baseline)
  • history of cerebrovascular events
  • other serious cardiac conditions that would raise the consequences of an increase in blood pressure or heart rate
  • Hypersensitivity to eszopiclone
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Liver disease
  • Adrenal insufficiency
  • Hypersensitivity to acetazolamide or other sulfonamides
  • Marked liver disease or impairment of liver function, including cirrhosis
  • bipolar disorder, mania
  • coronary artery disease
  • cardiac arrhythmias
  • hepatic disease
  • renal failure or impairment
  • cardiomyopathy (LVEF<50%) or heart failure
  • history of cardiac arrhythmias e.g., atrial fibrillation, QT prolongation
  • QT prolongation
  • Use of SSRIs/SNRIs
  • Contraindications for atomoxetine, including:
  • pheochromocytoma
  • benign prostatic hypertrophy, urinary retention
  • untreated narrow angle glaucoma
  • clinically significant constipation, gastric retention
  • advanced atherosclerosi
  • myasthenia gravis
  • pregnancy/breast-feeding
  • Contraindications for eszopiclone, including:
  • Pregnancy
  • Breast feeding
  • Contraindications for acetazolamide, including:
  • Hyperchloremic acidosis
  • Hypokalemia
  • Hyponatremia
  • Impaired kidney function
  • Contraindications for trazodone, including:
  • suicidal ideation
  • closed angle glaucoma
  • priapism
  • pregnancy/breast-feeding

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 21 and 70 years old?

Where in United States

  • Sleep Disorders Research Program Brigham and Women's HospitalBoston, United StatesContact: Ludovico MessineoTaking people

About the trial

What the trial wants to find out

Persistent obstructive sleep apnea (OSA) is common in people treated with mandibular advancement device (MAD) or hypoglossal nerve stimulation (HGNS). For most patients, these treatments are the last line of defense. If MAD or HGNS do not work, then patients are left to suffer the consequences of undertreated OSA. In this study, the investigators want to test the addition of a drug treatment to their regimen. Endotypes will be targeted pharmacologically with one of the following drugs: acetazolamide for a high loop gain, atomoxetine-plus-eszopiclone for poor pharyngeal muscle compensation, or trazodone for a low arousal threshold.

Read full original descriptionShow less

This aim is expected to provide treatment strategies for rescuing non-responders to MAD or HGNS therapy.

The 2 groups in the trial

  • PlaceboPlacebo, for comparison

    This is a two arm study. Patients will receive only one of the following drugs based on their altered sleep apnea trait. Patients with decreased arousal threshold will undergo treatment with placebo or Trazodone 100 mg in random order (one pill before 30 minutes before bedtime), patients with decreased pharyngeal muscle responsiveness will undergo treatment with placebo or Atomoxetine 80 mg + Eszopiclone 3 mg in random order (one pill before 30 minutes before bedtime), patients with increased loop gain will undergo treatment with placebo or Acetazolamide 500 mg in random order (one pill before 30 minutes before bedtime).

  • Interventional armExisting treatment, for comparison

    This is a two arm study. Patients will receive only one of the following drugs based on their altered sleep apnea trait. Patients with decreased arousal threshold will undergo treatment with placebo or Trazodone 100 mg in random order (one pill before 30 minutes before bedtime), patients with decreased pharyngeal muscle responsiveness will undergo treatment with placebo or Atomoxetine 80 mg + Eszopiclone 3 mg in random order (one pill before 30 minutes before bedtime), patients with increased loop gain will undergo treatment with placebo or Acetazolamide 500 mg in random order (one pill before 30 minutes before bedtime).

    Treatment: Acetazolamide, Trazodone, and Atomoxetine and eszopiclone

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Treating Residual OSA With Endotype-directed Pharmacotherapy (Aim 3)
Plain-language title
Added drugs for obstructive sleep apnea that remains despite device useGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT05293600, who can take part
Record updated
15 July 2026